EMPEROR_HFpEF
A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with preserved Ejection Fraction (HFpEF).
- Stadium
- klaar
- Middel
- empagliflozin
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 25 augustus 2017
- Last Patient In
- 10 januari 2020
- Last Patient Last Visit
- 18 april 2021
Studiedirecteur
